Description of Medical ServiceOncotype DX® is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.
Description of Medical ConditionOutside Australia, Oncotype DX® is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.
Reason for ApplicationRe-submission
Medical Service TypeInvestigative
Previous Application Numbers1342
Consultation SurveyFeedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1342.5 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).
PICO ConfirmationAs per application 1342
Public Summary DocumentPublic Summary Document (PDF 1276 KB)
Public Summary Document (Word 191 KB)